| Scott C Sims, MD | |
|
720 E 2nd Ave, Suite #203, Bowling Green, KY 42101-1778 | |
| (270) 843-5114 | |
| (270) 745-1230 |
| Full Name | Scott C Sims |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 43 Years |
| Location | 720 E 2nd Ave, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568425106 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 24986 (Kentucky) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 2022-02825 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| T J Samson Community Hospital | Glasgow, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| T J Samson Community Hospital | 0648182600 | 138 |
News Archive
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that the blood protein vitronectin is a promising drug target for dry age-related macular degeneration, a leading cause of vision loss in Americans 60 years of age and older.
A startling new preprint research paper posted to the medRxiv server warns against the use of commonly used non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the category of cyclooxygenase inhibitors (COX inhibitors) in patients with coronavirus disease 2019 (COVID-19).
In a new study published in the March issue of Radiology, researchers from Columbia University and the National Heart, Lung and Blood Institute have determined that an imaging exam of the heart using the latest generation of CT technology exposes patients to as much as 91 percent less radiation than standard helical CT scanning.
› Verified 6 days ago
| Entity Name | T J Samson Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477609865 PECOS PAC ID: 0648182600 Enrollment ID: O20040318001777 |
News Archive
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that the blood protein vitronectin is a promising drug target for dry age-related macular degeneration, a leading cause of vision loss in Americans 60 years of age and older.
A startling new preprint research paper posted to the medRxiv server warns against the use of commonly used non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the category of cyclooxygenase inhibitors (COX inhibitors) in patients with coronavirus disease 2019 (COVID-19).
In a new study published in the March issue of Radiology, researchers from Columbia University and the National Heart, Lung and Blood Institute have determined that an imaging exam of the heart using the latest generation of CT technology exposes patients to as much as 91 percent less radiation than standard helical CT scanning.
› Verified 6 days ago
| Entity Name | Southern Kentucky Nephrology Associates Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740310267 PECOS PAC ID: 4183654643 Enrollment ID: O20050816000173 |
News Archive
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that the blood protein vitronectin is a promising drug target for dry age-related macular degeneration, a leading cause of vision loss in Americans 60 years of age and older.
A startling new preprint research paper posted to the medRxiv server warns against the use of commonly used non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the category of cyclooxygenase inhibitors (COX inhibitors) in patients with coronavirus disease 2019 (COVID-19).
In a new study published in the March issue of Radiology, researchers from Columbia University and the National Heart, Lung and Blood Institute have determined that an imaging exam of the heart using the latest generation of CT technology exposes patients to as much as 91 percent less radiation than standard helical CT scanning.
› Verified 6 days ago
| Entity Name | Arh Tug Valley Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639949696 PECOS PAC ID: 4183953805 Enrollment ID: O20190905002344 |
News Archive
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that the blood protein vitronectin is a promising drug target for dry age-related macular degeneration, a leading cause of vision loss in Americans 60 years of age and older.
A startling new preprint research paper posted to the medRxiv server warns against the use of commonly used non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the category of cyclooxygenase inhibitors (COX inhibitors) in patients with coronavirus disease 2019 (COVID-19).
In a new study published in the March issue of Radiology, researchers from Columbia University and the National Heart, Lung and Blood Institute have determined that an imaging exam of the heart using the latest generation of CT technology exposes patients to as much as 91 percent less radiation than standard helical CT scanning.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott C Sims, MD 720 E 2nd Ave, Suite 203, Bowling Green, KY 42101-1778 Ph: (270) 843-5114 | Scott C Sims, MD 720 E 2nd Ave, Suite #203, Bowling Green, KY 42101-1778 Ph: (270) 843-5114 |
News Archive
Gilead Sciences, Inc. and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Under the terms of the agreement, Gilead will acquire CGI for up to $120 million, the majority as an upfront payment and the remaining based on clinical development progress, all of which will be financed through available cash on hand.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that the blood protein vitronectin is a promising drug target for dry age-related macular degeneration, a leading cause of vision loss in Americans 60 years of age and older.
A startling new preprint research paper posted to the medRxiv server warns against the use of commonly used non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the category of cyclooxygenase inhibitors (COX inhibitors) in patients with coronavirus disease 2019 (COVID-19).
In a new study published in the March issue of Radiology, researchers from Columbia University and the National Heart, Lung and Blood Institute have determined that an imaging exam of the heart using the latest generation of CT technology exposes patients to as much as 91 percent less radiation than standard helical CT scanning.
› Verified 6 days ago
Rodney T. Steff, DO Nephrology Medicare: Accepting Medicare Assignments Practice Location: 421 Us 31w Byp, Bowling Green, KY 42101 Phone: 270-782-0151 | |
Dr. Daniel R Long, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-745-1000 | |
Dr. Rance Wentworth, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-781-5111 Fax: 270-780-0462 | |
Pinky Dalal Gaba, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 427 Us 31w Byp, Bowling Green, KY 42101 Phone: 270-796-8800 Fax: 270-796-9328 | |
Ms. Uma Akkineni, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-796-6540 Fax: 270-796-6576 | |
Mohammed Kazimuddin, MD FACC FSCAI Nephrology Medicare: Accepting Medicare Assignments Practice Location: 825 Second Ave, Ste B1, Bowling Green, KY 42101 Phone: 270-782-0151 Fax: 270-782-7528 | |
Ann Scarlet Monardo, DO Nephrology Medicare: Medicare Enrolled Practice Location: 484 Golden Autumn Way Ste 201, Bowling Green, KY 42103 Phone: 270-393-2759 |